High dose chemotherapy - Results of American studies

Craig Nichols, Richard Maziarz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The role of high dose chemotherapy in the treatment of solid tumors is a subject of robust debate. Opinions range from the adoption of high dose chemotherapy with hematopoietic progenitor support as standard therapy for a number of solid tumors to the view that the application of such expensive and potentially toxic therapy is always experimental and should be the subject of clinical trials to define the role, if any. In germ cell tumors, the role of high dose chemotherapy is somewhat less contentious. In the US, high dose carboplatin and etoposide-based chemotherapy is routinely accepted as standard therapy for those patients failing prior standard dose regimens. There is increasing acceptance of the role of similar high dose therapy as a component of aggressive second line therapy and some initial acceptance of a potential role in primary treatment of poor risk disease. Formal study of these questions has been hampered by the rarity of the illness, the success of standard therapy and the smaller number of patients presenting with far advanced disease. This review will highlight the scientific underpinning of the role of high dose chemotherapy in multiply relapsed patients, as a component of initial salvage therapy and, finally as an attempt to improve outcome in patients with poor risk presenting features. As well, an attempt will be made to highlight where new prognostic information has influenced the design of current studies.

Original languageEnglish (US)
Pages (from-to)841-843
Number of pages3
JournalInternational Journal of Cancer
Volume83
Issue number6
DOIs
StatePublished - 1999

Fingerprint

Drug Therapy
Therapeutics
Salvage Therapy
Germ Cell and Embryonal Neoplasms
Poisons
Carboplatin
Etoposide
Neoplasms
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High dose chemotherapy - Results of American studies. / Nichols, Craig; Maziarz, Richard.

In: International Journal of Cancer, Vol. 83, No. 6, 1999, p. 841-843.

Research output: Contribution to journalArticle

@article{6e86cab7b05b4f949c8437d2ee02e94d,
title = "High dose chemotherapy - Results of American studies",
abstract = "The role of high dose chemotherapy in the treatment of solid tumors is a subject of robust debate. Opinions range from the adoption of high dose chemotherapy with hematopoietic progenitor support as standard therapy for a number of solid tumors to the view that the application of such expensive and potentially toxic therapy is always experimental and should be the subject of clinical trials to define the role, if any. In germ cell tumors, the role of high dose chemotherapy is somewhat less contentious. In the US, high dose carboplatin and etoposide-based chemotherapy is routinely accepted as standard therapy for those patients failing prior standard dose regimens. There is increasing acceptance of the role of similar high dose therapy as a component of aggressive second line therapy and some initial acceptance of a potential role in primary treatment of poor risk disease. Formal study of these questions has been hampered by the rarity of the illness, the success of standard therapy and the smaller number of patients presenting with far advanced disease. This review will highlight the scientific underpinning of the role of high dose chemotherapy in multiply relapsed patients, as a component of initial salvage therapy and, finally as an attempt to improve outcome in patients with poor risk presenting features. As well, an attempt will be made to highlight where new prognostic information has influenced the design of current studies.",
author = "Craig Nichols and Richard Maziarz",
year = "1999",
doi = "10.1002/(SICI)1097-0215(19991210)83:6<841::AID-IJC27>3.0.CO;2-C",
language = "English (US)",
volume = "83",
pages = "841--843",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - High dose chemotherapy - Results of American studies

AU - Nichols, Craig

AU - Maziarz, Richard

PY - 1999

Y1 - 1999

N2 - The role of high dose chemotherapy in the treatment of solid tumors is a subject of robust debate. Opinions range from the adoption of high dose chemotherapy with hematopoietic progenitor support as standard therapy for a number of solid tumors to the view that the application of such expensive and potentially toxic therapy is always experimental and should be the subject of clinical trials to define the role, if any. In germ cell tumors, the role of high dose chemotherapy is somewhat less contentious. In the US, high dose carboplatin and etoposide-based chemotherapy is routinely accepted as standard therapy for those patients failing prior standard dose regimens. There is increasing acceptance of the role of similar high dose therapy as a component of aggressive second line therapy and some initial acceptance of a potential role in primary treatment of poor risk disease. Formal study of these questions has been hampered by the rarity of the illness, the success of standard therapy and the smaller number of patients presenting with far advanced disease. This review will highlight the scientific underpinning of the role of high dose chemotherapy in multiply relapsed patients, as a component of initial salvage therapy and, finally as an attempt to improve outcome in patients with poor risk presenting features. As well, an attempt will be made to highlight where new prognostic information has influenced the design of current studies.

AB - The role of high dose chemotherapy in the treatment of solid tumors is a subject of robust debate. Opinions range from the adoption of high dose chemotherapy with hematopoietic progenitor support as standard therapy for a number of solid tumors to the view that the application of such expensive and potentially toxic therapy is always experimental and should be the subject of clinical trials to define the role, if any. In germ cell tumors, the role of high dose chemotherapy is somewhat less contentious. In the US, high dose carboplatin and etoposide-based chemotherapy is routinely accepted as standard therapy for those patients failing prior standard dose regimens. There is increasing acceptance of the role of similar high dose therapy as a component of aggressive second line therapy and some initial acceptance of a potential role in primary treatment of poor risk disease. Formal study of these questions has been hampered by the rarity of the illness, the success of standard therapy and the smaller number of patients presenting with far advanced disease. This review will highlight the scientific underpinning of the role of high dose chemotherapy in multiply relapsed patients, as a component of initial salvage therapy and, finally as an attempt to improve outcome in patients with poor risk presenting features. As well, an attempt will be made to highlight where new prognostic information has influenced the design of current studies.

UR - http://www.scopus.com/inward/record.url?scp=0032735908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032735908&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19991210)83:6<841::AID-IJC27>3.0.CO;2-C

DO - 10.1002/(SICI)1097-0215(19991210)83:6<841::AID-IJC27>3.0.CO;2-C

M3 - Article

C2 - 10597207

AN - SCOPUS:0032735908

VL - 83

SP - 841

EP - 843

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -